A study to understand the effectiveness of the drug pembrolizumab in treating breast cancer.
New York Presbyterian Hospital Weill Cornell Medical Center: New York, New York, United States, 10065
Trial Summary
In this trial, researchers will compare the effectiveness of adding Entinostat drug on top of Exemestane can better stop cancer spread for patients with Hormone Receptor-Positive Advanced Breast Cancer. Entinostat and Exemestane are hormone therapy drugs that help stops cancer growth in different ways. The study population is patients with hormone receptor-positive breast cancer. Participants are randomly assigned either Exemestane with placebo as therapy, or Exemestane and Entinostat as therapy.
Trial Design
1155 participants will be randomly divided into two groups. One group will not receive treatment, while the other group will receive Pembrolizumab as treatment.
Inclusion Criteria
1. 18 years or older.
2. Have triple-negative breast cancer.
3. Not planning to receive other treatment.
4. Do not currently have hepatitis B virus (HBV) or hepatitis C virus (HCV).
5. Other cancer treatments or general health related conditions must be satisfied.
Exclusion Criteria
1. Less than 18 years old.
Exclusion criteria are conditions or characteristics if they apply to you, may likely make you ineligible to participate in the study.
Inclusion criteria is a checklist of items, if they apply to you, may make you eligible to be included for the study.